Whitehawk Therapeutics (WHWK) Insider Reeve Buys 38,040 Shares

Insider Buying and Selling at Whitehawk Therapeutics, Inc.

Emma Reeve joined a large group of insiders who acquired shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK) on June 12, 2026. The group transaction involved multiple key figures each picking up 38,040 shares in the clinical-stage oncology therapeutics company. This cluster purchase highlights significant participation from leadership all on a single day.

Group Insider Activity on June 12

The June 12 transaction wasn't isolated to a single person. Alongside Emma Reeve, insiders Mohammad Hirmand, Behzad Aghazadeh, Baiteng Zhao, Richard Maroun, Neil Desai, and Caley Castelein each added 38,040 shares of the oncology biotech firm to their personal holdings. This coordinated buying wave follows earlier insider activity recorded earlier in the month, pointing to a shared view among company insiders as the shares trade around $4.16.

Whitehawk Therapeutics Stock Performance

Shares of Whitehawk Therapeutics trade on the Nasdaq exchange under the ticker WHWK. The stock changes hands around $4.16, resting just beneath its 50-day moving average of $4.29 while remaining comfortably above its 200-day moving average of $3.71. Over the past year, the equity has moved between a low of $1.82 and a high of $5.49, giving the Morristown-based company a market capitalization of roughly $230.3 million.

Analysts Set New Price Targets

Wall Street firms have kept a positive outlook on the clinical-stage biotech firm through recent months. On June 25, 2026, B. Riley Securities initiated coverage with a buy rating and a $10.00 price target. Later on July 13, 2026, Leerink Partners initiated an outperform rating with a $9.00 target, followed by Stifel initiating a buy rating with a $9.00 target on October 1, 2026. Overall, the stock holds a consensus buy recommendation with six analyst opinions and a mean price target of $7.50.

Inside Whitehawk Therapeutics

Whitehawk Therapeutics is a clinical-stage oncology therapeutics company based in Morristown, New Jersey. The firm develops technologies to establish tumor biology for cancer treatments, focusing on next-generation antibody-drug conjugate portfolios. Formerly known as Aadi Bioscience before changing its name in August 2021, the company employs 32 people and advances targeted cancer care.

What to Watch at WHWK

Investors will look ahead to the company's next earnings report, which is scheduled for November 5, 2026. Further SEC filings will also show whether insiders continue adding to their positions as the clinical-stage pipeline progresses. As always, insider transactions offer a window into leadership sentiment but remain backward-looking snapshots of corporate ownership.